March 1986
Volume 27, Issue 3
Free
Articles  |   March 1986
Therapeutic and systemic side effects of ocular beta-adrenergic antagonists in anesthetized dogs.
Investigative Ophthalmology & Visual Science March 1986, Vol.27, 401-405. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A L Svec, A M Strosberg; Therapeutic and systemic side effects of ocular beta-adrenergic antagonists in anesthetized dogs.. Invest. Ophthalmol. Vis. Sci. 1986;27(3):401-405.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Beta adrenergic antagonists, while useful in the treatment of glaucoma, can be absorbed transocularly causing a variety of systemic side effects. An adequate animal model which simultaneously indicates the intraocular pressure lowering effects as well as the systemic effects of ocularly applied beta-adrenergic antagonists would be highly useful. The pentobarbital anesthetized dog, instrumented to record blood pressure (BP) and heart rate (HR) and in which intraocular pressure (IOP) was measured with a pneumatonometer, was investigated. Isoproterenol iv dose-response curves were run and IOP measured before and hourly for 3 hr following ocular application of 50 microliters 0.5% RS-52367 (a Syntex beta-adrenergic antagonist), or dH2O control. Timolol and RS-52367 produced similar decreases in IOP. However, timolol decreased basal BP and HR, markedly inhibited isoproterenol-induced BP and HR responses, and also decreased contralateral IOP. Systemic effects of RS-52367 were far more mild. Since both the IOP lowering and systemic beta-adrenergic antagonist properties of timolol were elicited, the anesthetized dog appears to be an excellent animal model for examining the effects of beta-adrenergic antagonists applied topically to the eye.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×